



Altimune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

August 5, 2026 at 8:00 AM EDT

GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- [Altimune, Inc.](#) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026.

Altimune management will host a conference call at 8:30 a.m. ET on August 12 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimune's Investor Relations [website](#).

Participants who would like to join the call may register [here](#) to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months.

About Altimune

Altimune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's lead candidate, pemvidutide, is a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [X](#)

Investor Contact:

Luis Sanay, CFA
Vice President, Investor Relations
ir@altimmune.com

Media Contact:

Real Chemistry
altimmune@realchemistry.com

